HomeInsightsPE

Alembic Pharmaceuticals Ltd PE Ratio

Alembic Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 1.2 Cr

Volume transacted

stocks purchased

10.3 K

stocks traded

Last Updated time: 20 Sep 9.00 AM

Image

Alembic Pharmaceuticals Ltd

NSE: APLLTD

PE

35.8

Last updated: 20 Sep 9.00 AM

Key Highlights

  • The P/E Ratio of Alembic Pharmaceuticals Ltd is 35.8 as of 20 Sep 9.00 AM.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 17.1 on March 2019 to 31.4 on March 2024 . This represents a CAGR of 10.66% over 6 years. .
  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 1146 as of 19 Sep 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 21.8. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.2. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 164.1. The PE Ratio of Textiles industry is 35.7. In 2024.

Historical P/E Ratio of Alembic Pharmaceuticals Ltd

No data available

Company Fundamentals for Alembic Pharmaceuticals Ltd

No data available

Image

Alembic Pharmaceuticals Ltd

NSE: APLLTD

PRICE

1146.5

-42.25 (-3.55%)

stock direction

Last updated: 19 Sep 15:30

Share price Over Time

1M

1Y

3Y

5Y

Monitoring Alembic Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Share Price

Date
leftPriceleft
19 Sep 20241146.5
18 Sep 20241188.75
17 Sep 20241200.4
16 Sep 20241182.3
13 Sep 20241208.55
12 Sep 20241216.4
11 Sep 20241248.6
10 Sep 20241243.25
09 Sep 20241204.15
06 Sep 20241107.65

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Alembic Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Alembic Pharmaceuticals Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Alembic Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Alembic Pharmaceuticals Ltd

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA.
  • The company is one of the leaders in branded generics in India.
  • Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business.
  • As per the scheme of arrangement, the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharmaceuticals appoints Head - Technical Operations (Sterile & Oncology)

Alembic Pharmaceuticals has appointed Sudhakar Pandiyan as Head - Technical Operations (St...

Read more

16 Sep 202417:45

News

Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

05 Sep 202413:21

News

Alembic Pharma gains after receiving USFDA nod for Betamethasone Valerate Foam

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

26 Aug 202409:55

News

Alembic Pharmaceuticals receives USFDA approval for Betamethasone Valerate Foam

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

24 Aug 202414:03

News

Alembic Pharma gets USFDA nod for Betamethasone Valerate Foam

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

24 Aug 202416:59

News

Alembic Pharma receives USFDA approval for Dabigatran Etexilate Capsules

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration...

Read more

13 Aug 202412:15

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Alembic Pharmaceuticals Ltd

What is the current PE Ratio of Alembic Pharmaceuticals Ltd?

The Current PE Ratio of Alembic Pharmaceuticals Ltd is 35.77 as on 20 Sep 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 20 Sep 2024.

What was the PE Ratio of Alembic Pharmaceuticals Ltd last year?

The PE Ratio of Alembic Pharmaceuticals Ltd was 28.5 last year, now the PE ratio is 35.77, showing a year-on-year growth of 25.5%.

What does the PE Ratio of Alembic Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Alembic Pharmaceuticals Ltd is 35.77. This ratio indicates that investors are willing to pay 35.77 times the earnings per share for each share of Alembic Pharmaceuticals Ltd.

What is the PE Ratio Growth of Alembic Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Alembic Pharmaceuticals Ltd grew by 25.5% whereas, the EPS ratio grew by -19.3.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*